Request Demo
Last update 08 Mar 2025
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Last update 08 Mar 2025
Overview
Basic Info
Introduction Suzhou Suncadia Biopharmaceuticals Co., Ltd., situated in Suzhou Industrial Park, is an independent subsidiary wholly owned by Jiangsu Hengrui Medicine Co., Ltd., founded in September 2015. This enterprise is dedicated to the research and development, pilot production, commercial manufacturing, and distribution of innovative biopharmaceuticals. Its mission revolves around delivering pioneering treatments in areas such as oncology, autoimmune diseases, and hypercholesterolemia to patients across China and the world. |
Tags
Neoplasms
Digestive System Disorders
Respiratory Diseases
Monoclonal antibody
Antibody drug conjugate (ADC)
Antibody fusion proteins
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
NCT06860750
A Randomized, Double-blind, Multicenter, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial Spondyloarthritis
NCT06844474
A Phase II, Multicenter, Open-Label Clinical Study to Evaluate the Safety, Tolerability and Efficacy of SHR-1826 for Injection in Patients With NSCLC
NCT06840002
An Open, Multicenter Phase Ib / II Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
100 Clinical Results associated with Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Login to view more data
Login to view more data
01 Feb 2023Translational oncology
The Current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity
Review
Author: Pan, Chao ; Wang, Yang ; Qu, Bo ; Li, Cuihua ; Wei, Qiang ; Xing, Hui ; Li, Hui
ICI-related hepatotoxicity (IRH) is becoming more and more common as immune checkpoint inhibitors (ICIs) have begun to be increasingly approved and used in combination with other anti-tumor drugs worldwide. Steroids are the first choice for the treatment of IRH, but the subsequent optimal treatment algorithm remains unclear if the disease progresses to steroid-refractory IRH. Therefore, in this paper we reviewed all the pertinent literature on steroid-refractory IRH to the greatest extent possible in an attempt to provide information on which to base an update of the treatment algorithm for steroid-refractory IRH.
100 Deals associated with Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Login to view more data
100 Translational Medicine associated with Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 11 Mar 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
3
10
Phase 1
Phase 2
9
6
Phase 3
NDA/BLA
2
3
Approved
Other
1
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free